Vitamin D3 + K2: The Longevity Pairing

Bio Precision Aging Evidence Grade

Overall Evidence Grade: B− | Promising Biology, Limited Clinical Outcome Evidence

Mechanism: ★★★★★ Strong: Vitamin D and vitamin K2 have well-established roles in calcium regulation and the activation of calcium-regulating proteins.

Biomarker Evidence: ★★★★★ Strong: Randomized trials consistently show that K2 supplementation changes dp-ucMGP, a marker of vitamin K–dependent protein activation.

Bone Health: ★★★★☆ Moderate to Strong: Evidence supports correcting vitamin D deficiency and suggests modest benefits from calcium plus vitamin D in certain populations, particularly those at increased risk of bone loss.

Cardiovascular Protection: ★★☆☆☆ Limited: Despite favorable changes in vitamin K–related biomarkers, randomized trials have not demonstrated that D3/K2 supplementation slows established vascular or aortic valve calcification or reduces cardiovascular events.

Longevity / Healthspan: ★★☆☆☆ Limited: There is a compelling biological rationale, but direct evidence that D3/K2 supplementation extends lifespan or meaningfully improves healthspan is currently insufficient.

BPA Take

Yes, there are clear benefits here but it is not yet proven as a cardiovascular or longevity intervention.

The strongest case is for correcting documented vitamin D deficiency and taking an individualized approach to bone and calcium health. K2 is biologically interesting and appears to have a favorable safety profile, but its ability to translate those biological effects into better long-term clinical outcomes remains an open question.

Evidence grades reflect the strength and consistency of the human evidence reviewed in this article, not the popularity of the intervention or the strength of its biological theory.

Vitamin D has become almost synonymous with healthy aging. It is linked to bones, muscles, immune function, and a long list of other biological processes. Vitamin K2, meanwhile, has emerged as a popular companion to vitamin D, particularly in the longevity and supplement world.

The theory behind combining the two is compelling. Vitamin D helps your body absorb calcium. Vitamin K2 helps activate proteins that tell calcium where it belongs—primarily in your bones rather than in places where you don't want it, such as the walls of your arteries.

That leads to an intriguing question:

Could taking vitamin D3 and K2 together help strengthen bones while reducing the risk of calcium accumulating in the cardiovascular system?

It is an attractive idea, but when we move beyond the biochemical story and look at human clinical trials, the picture becomes considerably more nuanced. For anyone interested in longevity, that distinction matters. The goal isn't simply to find supplements that make biological sense. The goal is to determine whether changing a biological pathway actually produces better health outcomes.

So, what does the evidence tell us?

Why Vitamin D and K2 Are Being Talked About Together

To understand the appeal of the D3/K2 combination, start with calcium. Calcium is essential for life. We need it for strong bones and teeth, muscle contraction, nerve signaling, and other basic functions. But calcium also has to be carefully controlled. Too little in the wrong place can weaken bones. Too much in the wrong place can contribute to calcification of tissues.

This creates something researchers sometimes describe as the "calcium paradox."

People can lose calcium from their bones while calcium simultaneously accumulates in arteries and heart valves.

That may sound contradictory, but the body's calcium-regulating system is considerably more complicated than simply having "too much" or "too little" calcium.

This is where vitamins D and K enter the story. Vitamin D3 increases calcium absorption from the intestine and helps regulate the production of proteins involved in calcium metabolism. Vitamin K2, in turn, acts as a cofactor that activates several of those proteins.

In simple terms, vitamin D helps make the machinery, while vitamin K helps turn part of that machinery on.

That biological relationship is well established. What is less certain is whether taking the two as supplements together produces meaningful improvements in long-term cardiovascular or longevity outcomes. And that is where the story gets interesting.

Vitamin D Isn't Just About Sunshine

Vitamin D3, or cholecalciferol, can be produced in the skin when it is exposed to ultraviolet-B radiation. It is also found in foods such as fatty fish, egg yolks, and liver, as well as in fortified foods. Once vitamin D enters the body, it goes through a series of steps before becoming biologically active.

One of the most important measurements is 25-hydroxyvitamin D, or 25(OH)D. This is the form measured in routine blood testing to determine vitamin D status.

Vitamin D deficiency is common as roughly 25% of the U.S. population and as many as 60% of Central Europeans have 25(OH)D levels below 20 ng/mL. Low levels have been associated with increased disease and mortality risk in observational studies. But there is an important distinction here.

How much can sunlight move your level?

Sunlight is the body's main vitamin D source, but its ceiling is lower than many people assume. In Hawaii, young adults averaging about 29 hours of sun per week had a mean of only 31.6 ng/mL, half were under 30, and the highest anyone reached was 62 ng/mL. Traditional Maasai and Hadzabe in Tanzania, outdoors most of the day near the equator, averaged about 46 ng/mL (115 nmol/L), with a range of roughly 23 to 68 ng/mL. Heaney's Omaha study estimated that summer sun stores supplied over 80% of winter needs, with men using 3,000 to 5,000 IU per day. So sun alone tends to land people in the 30 to 60 ng/mL zone; reaching 70 to 90 usually requires supplements.

Analogy: Think of skin as a faucet with an automatic shutoff. Once enough previtamin D is made, extra UV breaks it down into inactive compounds, so the tank fills to a natural level and stops. Pills bypass that shutoff, which is why they can push levels above what sun alone produces.

An association is not the same thing as proof that taking more vitamin D will prevent disease.

That distinction becomes particularly important when we look at the large randomized trials later in this article.

Where K2 Fits In

Vitamin K comes in several forms. Vitamin K1 is found primarily in leafy green vegetables, while vitamin K2 refers to a family of compounds called menaquinones. K2 is found in foods including fermented products such as natto, certain cheeses, and some animal products.

Two forms receive particular attention: MK-7 and MK-4.

MK-7 has a relatively long half-life, meaning it remains in circulation longer and can provide more sustained activity. MK-4 behaves differently and has been used pharmacologically for osteoporosis, particularly in Japan.

The reason K2 has attracted so much attention in longevity circles is not simply that it is "good for bones." It has a role in activating proteins involved in calcium handling throughout the body. And that brings us to two proteins that are central to the D3/K2 story.

The Two Proteins That Make the D3/K2 Story So Interesting

One is osteocalcin, which is produced by bone-forming cells.

The other is matrix Gla protein, or MGP, which is produced in vascular tissue and plays an important role in protecting arteries and heart valves from calcification.

Vitamin D helps stimulate production of both proteins.

But there is a catch. The proteins initially exist in an inactive form. Vitamin K is required to activate them through a biochemical process called carboxylation.

Think of it this way: Vitamin D helps produce the instructions. Vitamin K helps activate the finished product. When osteocalcin is properly activated, it can bind calcium within the bone matrix and support mineralization.

Activated MGP, meanwhile, can bind calcium crystals in the arterial wall and inhibit their growth. This is one reason K2 has become so interesting to researchers studying aging.

The same calcium-regulating system touches two areas that become increasingly important as we get older:

Bone health and vascular health.

There is even a blood marker that researchers can use to see whether vitamin K is having this biological effect. It is called dp-ucMGP, and it reflects the amount of undercarboxylated—essentially inactive—MGP circulating in the blood.

Across the randomized trials reviewed for this article, K2 supplementation consistently lowered dp-ucMGP. In other words, researchers could clearly see that K2 was doing something biologically measurable.

But—and this is a very important "but"—a biological effect is not necessarily a clinical benefit.

The Big Question: Does It Actually Protect Your Arteries?

This is where the headline gets less exciting. One of the largest randomized trials to examine the question was published in Circulation in 2022. Researchers enrolled 365 men who already had significant aortic valve calcification.

Participants received either 720 micrograms of MK-7 plus 25 micrograms of vitamin D3 each day or a placebo for two years. The researchers measured progression of aortic valve calcification using cardiac CT scans. The result?

There was no significant difference between the groups.

The combination successfully changed the biological marker dp-ucMGP. But that did not translate into slower progression of aortic valve calcification.

There were also no significant differences in aortic valve area, peak blood-flow velocity, or progression of coronary artery calcification.

That is a classic example of why longevity science requires us to look beyond biomarkers.

The supplement changed the biology.

It just didn't produce the expected clinical outcome—at least in this particular population over two years.

Another Trial, Another Reality Check

A second important randomized trial looked at 178 people receiving maintenance hemodialysis. This is a particularly high-risk population because kidney disease is associated with a high burden of vascular calcification. Participants received MK-7 or control for 18 months. Again, vitamin K2 clearly affected the biological marker.

Again, however, researchers did not find a significant difference in coronary artery calcification, aortic valve calcification, arterial stiffness, or major cardiovascular events.

The hazard ratio for major adverse cardiac events was 0.98, with a 95% confidence interval of 0.50–1.94.

In other words, the intervention changed the marker researchers expected it to change—but the improvement did not translate into a measurable cardiovascular advantage in this trial. That doesn't prove K2 is useless. It does mean we should be careful about claiming that K2 supplements prevent or reverse arterial calcification.

The current randomized evidence doesn't establish that.

What About Bones?

The bone story is somewhat more encouraging—but it still isn't as simple as "take D3 and K2 and your fracture risk disappears."

Several systematic reviews have examined calcium and vitamin D supplementation in postmenopausal women.

A 2025 meta-analysis that pooled 11 randomized trials involving 43,869 participants found modest improvements in bone mineral density at some sites, including the pelvis.

However, the overall reduction in clinical fracture risk was not statistically significant, with pooled relative risks in the range of 0.95–0.98.

An earlier meta-analysis found a significant reduction in hip fracture risk, with a relative risk of 0.864. It also suggested that dairy products fortified with calcium and vitamin D could perform better for bone mineral density than isolated supplements.

So the takeaway isn't that calcium and vitamin D don't matter.

They clearly matter when someone is deficient or at elevated risk for bone loss.

The more nuanced point is that supplementation doesn't automatically translate into dramatically lower fracture risk for everyone.

Again, context matters.

And Then There Is Vitamin D Alone

The broader vitamin D research provides another important reality check.

Researchers have now conducted several very large randomized trials examining whether vitamin D supplementation can prevent major diseases.

A 2022 review of the VITAL, ViDA, and D2d trials—collectively involving more than 30,000 participants—concluded that vitamin D supplementation did not reduce cancer, cardiovascular events, falls, or progression to type 2 diabetes in adults who were already vitamin D sufficient.

There was some suggestion that benefits might be concentrated among people who started out deficient.

A separate analysis of the VITAL trial looked specifically at kidney function.

Researchers found that 2,000 IU of vitamin D3 daily reliably increased blood vitamin D levels and lowered parathyroid hormone across different levels of kidney function.

But it did not significantly reduce cardiovascular events or cancer incidence.

This is important because vitamin D has sometimes been marketed as though more is inherently better.

The clinical trials don't support that idea. If you're already replete, taking more vitamin D does not necessarily mean more protection.

There Is Still Some Debate

The vitamin D conversation isn't completely settled. A 2025 review by Grant and colleagues argues that many randomized trials may underestimate the benefits of vitamin D because they included people who were already relatively sufficient and used doses that were too modest.

The authors argue for higher blood 25(OH)D concentrations—potentially above 30 ng/mL and perhaps in the 40–70 ng/mL range—and suggest doses of approximately 2,000–6,000 IU per day in some circumstances.

But there is an important caveat. That position relies substantially on observational evidence and represents a minority, guideline-critical interpretation of the evidence.

It does not erase the results of the large randomized trials. For someone interested in precision aging, this is exactly the kind of disagreement worth paying attention to.

Science doesn't always give us a single clean answer.

Sometimes the smartest approach is to understand why credible researchers interpret the same evidence differently—and then avoid overstating what we know.

So Who Might Actually Benefit?

The strongest case for vitamin D supplementation remains someone who is actually deficient. If a blood test shows a 25(OH)D level below 20 ng/mL, correcting that deficiency is a much more evidence-based proposition than taking large doses simply because vitamin D has been associated with longevity. The case for K2 is more complicated.

There is a strong biological rationale for its role in calcium metabolism, and K2 consistently changes the relevant biochemical marker in clinical trials.

But we don't yet have convincing evidence that supplementation prevents cardiovascular events or reverses established arterial or valve calcification. There is an interesting unanswered question here.

What if intervention occurs earlier?

The major cardiovascular trials involved people who already had substantial calcification or were at very high risk. It remains possible that influencing calcium metabolism before significant calcification develops could produce a different outcome.

That hypothesis makes biological sense. But it remains a hypothesis and it has not yet been established in randomized clinical trials. And that distinction—between what is plausible and what is proven—is at the heart of precision aging.

What About Dosage?

For generally healthy adults who are already vitamin D sufficient, the source material identifies 1,000–2,000 IU of vitamin D3 per day as a common maintenance range.

For documented deficiency, higher doses may sometimes be used for a limited period under medical supervision, with laboratory monitoring. Most people require up to around 5000 IU a day to get there levels >50 ng/mL.

For K2, MK-7 is generally favored because of its longer activity in the body. A commonly used supplemental range is approximately 90–360 micrograms per day,

although the cardiovascular trial discussed earlier used 720 micrograms per day.

A reasonable general starting point discussed in the source material is 100–200 micrograms of MK-7 per day. Because both vitamins are fat-soluble, they are generally taken with a meal containing some dietary fat. But dosing should not be viewed as a one-size-fits-all prescription.

Your baseline vitamin D level, diet, kidney function, medications, calcium status, and overall health profile can all change the equation.

The Safety Question Matters

Vitamin D is generally well tolerated at doses up to approximately 5,000 IU per day, but higher doses should not be treated casually. Too much vitamin D can increase calcium levels in the blood, potentially causing nausea, weakness and, in severe or chronic cases, kidney-related complications.

In the large VITAL trial, 2,000 IU per day was not associated with a significant excess of adverse events over 5.3 years. K2 also demonstrated a favorable safety profile in the trials reviewed, including studies using doses as high as 720 micrograms per day.

But there is one particularly important exception. If you take warfarin or another vitamin K antagonist anticoagulant, vitamin K2 is not something to add casually.

Vitamin K can interfere directly with the mechanism of these medications, making medical supervision and INR monitoring essential. Direct oral anticoagulants, or DOACs, do not have the same interaction, but medication changes should still be discussed with the prescribing clinician.

People with a history of hypercalcemia, hyperparathyroidism, sarcoidosis or other granulomatous diseases, active kidney stones, or advanced chronic kidney disease also warrant individualized guidance before supplementing.

The Bottom Line: Follow the Biology, But Don't Stop There

The D3/K2 combination has one of those scientific stories that is easy to love. Vitamin D increases the production of important calcium-regulating proteins.

Vitamin K activates them.

One supports the system; the other helps put the system to work. And the laboratory evidence is convincing that K2 changes the biological pathway researchers expect it to change. But here's the part that matters most: Changing a biomarker isn't the same thing as changing your health.

The two major cardiovascular randomized trials reviewed here found that K2 changed the relevant biomarker but did not significantly slow established vascular or valvular calcification or reduce cardiovascular events.

Likewise, large vitamin D trials have not demonstrated broad protection against cardiovascular disease, cancer, falls, or diabetes in people who are already vitamin D sufficient. That doesn't make vitamin D or K2 irrelevant.

It means we need to be more precise about who is likely to benefit, why they might benefit, and what outcome we're actually trying to improve. For precision aging, the evidence currently supports a fairly measured approach. Correct documented vitamin D deficiency.

Pay attention to bone health, particularly as fracture risk increases with age.

Consider K2 as a biologically plausible component of a broader calcium-management strategy, while recognizing that its cardiovascular benefits have not yet been demonstrated in hard clinical outcomes.

And above all, don't confuse a compelling mechanism with a proven longevity intervention.

That's the difference between following a supplement trend and practicing evidence-based precision aging.

The next generation of research may tell us whether intervening earlier—before significant vascular calcification develops—changes the equation. For now:

The biology is compelling. The biomarkers are promising. The clinical outcomes are still a work in progress.

And that's exactly where the headline ends and the real science begins. Studies showing benefit at higher levels

1. McDonnell 2016 (all cancers). 2,304 women aged 55+. At ≥40 ng/mL, cancer risk was 67% lower than at <20 ng/mL (HR 0.33, 95% CI 0.12 to 0.90). https://doi.org/10.1371/journal.pone.0152441

2. McDonnell 2018 (breast cancer). 5,038 women. At ≥60 ng/mL, risk was 80% lower than at <20 (HR 0.20, p=0.03). This is the only study in this list that grouped people within the 50 to 90 range. https://doi.org/10.1371/journal.pone.0199265

3. Garland 2007 (breast cancer pooled analysis). About 52 ng/mL was associated with roughly 50% lower risk than <13 ng/mL. https://doi.org/10.1016/j.jsbmb.2006.12.007

4. McDonnell 2017 (preterm birth). 1,064 pregnancies. At ≥40 ng/mL, preterm birth risk was 62% lower (adjusted OR 0.41). https://doi.org/10.1371/journal.pone.0180483

5. Lappe 2007 (RCT). 1,100 IU D3 plus calcium lowered cancer risk (RR 0.40; 0.23 after the first year). https://doi.org/10.1093/ajcn/85.6.1586

6. McCullough 2019 (colorectal, 17 cohorts). At 35 to 40 ng/mL, risk was 27% lower (RR 0.73). https://doi.org/10.1093/jnci/djy087

7. Hahn 2022 (VITAL). 2,000 IU/day reduced autoimmune disease by 22% (HR 0.78). https://doi.org/10.1136/bmj-2021-066452

8. Keum 2019 (meta-analysis of RCTs). Supplementation reduced cancer deaths by 13% (RR 0.87). https://doi.org/10.1093/annonc/mdz059

Evidence that tempers this

• VITAL (25,871 people) found no reduction in cancer incidence (HR 0.96). https://doi.org/10.1056/NEJMoa1809944

• Lappe 2017 reached 43.9 ng/mL and found a 30% reduction, but it missed significance (p=0.06). https://doi.org/10.1001/jama.2017.2115

• In McCullough 2019, the colorectal benefit stopped increasing above 40 ng/mL. https://doi.org/10.1093/jnci/djy087

• In a Danish cohort of 247,574 people (Durup 2012), mortality was 42% higher at 56 ng/mL than at 20 ng/mL. https://doi.org/10.1210/jc.2012-1176

• None of the studies above analyzed people at 70 to 90 ng/mL as a separate group.

Other References

[1] Hariri E, Kassis N, Iskandar JP, Schurgers LJ, et al. Vitamin K—a neglected player in cardiovascular health: a narrative review. Open Heart. 2021;8(2). PMID: 34785587. https://doi.org/10.1136/openhrt-2021-001715

[2] Diederichsen ACP, Lindholt JS, Möller S, et al. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial. Circulation. 2022;145(18):1387-1397. PMID: 35465686. https://doi.org/10.1161/CIRCULATIONAHA.121.057008

[3] Haroon S, Davenport A, Ling LH, et al. Randomized Controlled Clinical Trial of the Effect of Treatment with Vitamin K2 on Vascular Calcification in Hemodialysis Patients (Trevasc-HDK). Kidney Int Rep. 2023;8(9):1741-1751. PMID: 37705910. https://doi.org/10.1016/j.ekir.2023.06.011

[4] Singh W, Kushwaha P, Kushwaha SP. Exploring Menatetrenone: Origin, Chemistry, Therapies and Delivery. J Am Nutr Assoc. 2025;44(6):508-520. PMID: 39898865. https://doi.org/10.1080/27697061.2025.2460539

[5] Cong B, Zhang H. The effects of combined calcium and vitamin D supplementation on bone mineral density and fracture risk in postmenopausal women with osteoporosis: a systematic review and meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2025;26(1):928. PMID: 41063100. https://doi.org/10.1186/s12891-025-09089-7

[6] Liu C, Kuang X, Li K, Guo X, Deng Q, Li D. Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Food Funct. 2020;11(12):10817-10827. PMID: 33237064. https://doi.org/10.1039/d0fo00787k

[7] Bouillon R, Manousaki D, Rosen C, Trajanoska K, Rivadeneira F, Richards JB. The health effects of vitamin D supplementation: evidence from human studies. Nat Rev Endocrinol. 2022;18(2):96-110. PMID: 34815552. https://doi.org/10.1038/s41574-021-00593-z

[8] Limonte CP, Zelnick LR, Hoofnagle AN, et al. Effects of Vitamin D Supplementation on Cardiovascular and Cancer Outcomes by eGFR in VITAL. Kidney360. 2022;3(12):2095-2105. PMID: 36591342. https://doi.org/10.34067/KID.0006472022

[9] Grant WB, Wimalawansa SJ, Pludowski P, Cheng RZ. Vitamin D: Evidence-Based Health Benefits and Recommendations for Population Guidelines. Nutrients. 2025;17(2):277. PMID: 39861407. https://doi.org/10.3390/nu17020277

Medical Disclaimer

This article is provided for educational purposes only and does not constitute individualized medical advice. Consult a qualified healthcare provider before beginning, stopping, or modifying any supplement or medication regimen, particularly if you take anticoagulants or have a history of hypercalcemia, kidney disease, or granulomatous illness.